Enzymatica receives record order from STADA Arzneimittel AG
2017年6月14日 - 3:00PM
Press release
Lund, June 14, 2017
Enzymatica has received its
largest order to date for a total of about SEK 12 million.
The global pharmaceutical company STADA
Arzneimittel AG ("STADA"), headquartered in Germany, has ordered
Enzymatica's cold product ColdZyme® Mouth
spray for the German, Belgian and Austrian markets for the common
cold season after the summer.
The order is a result of the cooperation agreement
that Enzymatica and STADA reached in February 2017. The agreement
grants STADA exclusive rights to sell, market and distribute
ColdZyme in Germany, the largest market for OTC products in Europe,
as well as in Belgium and Austria.
"We are now beginning to see the results of our
efforts to sign agreements with international distributors for the
major OTC markets. The order is the largest in Enzymatica's history
and is worth much more than the entire sales of SEK 9.6 million for
the first quarter this year. The order confirms the commercial
potential of ColdZyme and our technology platform," says Fredrik
Lindberg, CEO of Enzymatica.
Enzymatica expects to deliver the order at the end
of the summer and the revenue will have an impact on the company's
third quarter sales.
STADA is a publicly-listed German company with a
traditionally strong presence in Europe, especially in Germany.
STADA is an international company and its five largest markets are
Germany, Russia, the UK, Italy and Spain. In 2016 the STADA Group
generated sales of EUR 2,139 million and had 10,839 employees all
over the world.
The information in this press
release is information that Enzymatica is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out below, on June 14, 2017 at 08.00.
For
more information please contact:
Fredrik Lindberg, CEO, Enzymatica
AB
Tel: +46 (0)708-86 53 70 | Email:
fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica AB is a medical device company that develops and sells
medical devices for infection-related diseases. In just a short
period of time, the company developed ColdZyme®, a unique mouth
spray for colds, launched the product in eight countries and became
established among the top-selling cold products (denominated in
SEK) at Swedish pharmacies. The strategy is to continue to grow by
strengthening the Company's position in existing markets and
expanding into new geographic markets through established partners.
The company is headquartered in Lund and is listed on Nasdaq First
North. For more information please
visit: www.enzymatica.se.
Enzymatica's Certified Adviser is Erik Penser
Bank.
Press Release (PDF)
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
過去 株価チャート
から 8 2024 まで 9 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
過去 株価チャート
から 9 2023 まで 9 2024